Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-06-10T17:17:44.380Z Has data issue: false hasContentIssue false

A Scoping Review on Category A Agents as Bioweapons

Published online by Cambridge University Press:  07 October 2021

Sarah L. Beale*
Affiliation:
National University, Community Health, San Diego, CaliforniaUSA
Tara Rava Zolnikov
Affiliation:
National University, Community Health, San Diego, CaliforniaUSA
Casey Mace Firebaugh
Affiliation:
National University, Community Health, San Diego, CaliforniaUSA Central Washington University, Department of Health Sciences, Ellensburg, WashingtonUSA
*
Correspondence: Sarah L. Beale, MPH, National University, Community Health, San Diego, CaliforniaUSA, E-mail: s.beale3813@student.nu.edu

Abstract

Category A agents are biological pathogens that could pose a threat to health and human safety if used as bioweapons. The exploration and possibility of these threats must be comprehensively reviewed to create a preparedness plan to recognize outbreaks, to educate the public, and to offer vaccinations and/or treatment options, if available. A scoping review using PRISMA guidelines was performed to categorize current information on Category A biological agents as well as understand their potential for future threats. The results used 34 articles and found that while botulin neurotoxins were the most lethal, anthrax posed the most likely threat for use as a bioweapon. Most research was conducted on plague, though it is not the most likely threat. Smallpox is the most likely agent to vaccinate against as there is already a working vaccine that has proven effective and the issue at hand is the need for a larger stockpile. Ultimately, preparedness efforts should include vaccinations and continued research and development of them. Category A agents are a serious public health concern; updated and reformed bioterrorism preparedness plans could greatly minimize panic and mortality.

Type
Research Report
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the World Association for Disaster and Emergency Medicine

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Disease Control and Prevention (CDC). Bioterrorism Agents/Diseases (by category). Emergency Preparedness & Response. https://emergency.cdc.gov/agent/agentlist-category.asp#a. Accessed June 2021.Google Scholar
Khardori, N, Kanchanapoom, T. Overview of biological terrorism: potential agents and preparedness. Clinical Microbiology Newsletter. 2005;27(1):18.CrossRefGoogle Scholar
Carus, WS. A Short History of Biological Warfare: From Pre-History to the 21st Century. Washington, DC USA: National Defense University Press; 2017.Google Scholar
Frischknecht, F. The history of biological warfare. EMBO Reports. 2003;4(65).CrossRefGoogle ScholarPubMed
Arnon, SS, Schechter, R, Inglesby, TV, et al. Botulinum toxin as a biological weapon. JAMA. 2001;285(8):10591070.CrossRefGoogle ScholarPubMed
Jernigan, DB, Raghunathan, PL, Bell, BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8(10):10191028.CrossRefGoogle ScholarPubMed
Riedel, S. Biological warfare and bioterrorism: a historical review. Baylor University Medical Center Proceedings. 2004;17(4):400406.CrossRefGoogle ScholarPubMed
Roffey, R, Lantorp, K, Tegnell, A, Elgh, F. Biological weapons and bioterrorism preparedness: importance of public-health awareness and international cooperation. Clin Microbiol Infect. 2002;8(8):522528.CrossRefGoogle ScholarPubMed
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Open Med. 2009;3(3):123130.Google ScholarPubMed
Mateen, FJ, Oh, J, Tergas, AI, Bhayani, NH, Kamdar, BB. Titles versus titles and abstracts for initial screening of articles for systematic reviews. Clin Epidemiol. 2013;5:8995.CrossRefGoogle ScholarPubMed
Ahn, E, Kang, H. Introduction to systematic review and meta-analysis. Korean Journal of Anesthesiology. 2018;71(2):103112.CrossRefGoogle ScholarPubMed
Borio, L, Inglesby, T, Peters, CJ, et al. Hemorrhagic fever viruses as biological weapons. JAMA. 2002;287(18):23912405.CrossRefGoogle ScholarPubMed
Dizer, U, Kenar, L, Ortatatli, M, Karayilanoglu, T. How to weaponize anthrax? Eastern Journal of Medicine. 2004;9(1):1316.Google Scholar
US Food and Drug Administration. Vaccines - Anthrax. https://www.fda.gov/biologicsbloodvaccines/vaccines/ucm061751.htm. Accessed June 2021.Google Scholar
Hendricks, KA, Wright, ME, Shadomy, SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):e130687.CrossRefGoogle Scholar
Dhaked, RK, Singh, MK, Singh, P, Gupta, P. Botulinum toxin: bioweapon and magic drug. Indian Journal of Medical Research. 2010;132(5):489503.Google ScholarPubMed
Center for Infectious Disease Research and Policy. Plague. http://www.cidrap.umn.edu/infectious-disease-topics/plague#overview&1-3. Accessed June 2021.Google Scholar
Inglesby, TV, Dennis, DT, Henderson, DA, et al. Plague as a biological weapon. JAMA. 2000;283(17):22812290.CrossRefGoogle ScholarPubMed
Feodorova, VA, Motin, VL. Plague vaccines: current developments and future perspectives. Emerg Microbes Infect. 2012;1(1):15.CrossRefGoogle ScholarPubMed
Bourzac, K. Smallpox: historical review of a potential bioterrorist tool. Journal of Young Investigators. 2002;6(3).Google Scholar
Cohen, J. BIOTERRORISM: smallpox vaccinations: how much protection remains? Science. 2001;294(5544):985.CrossRefGoogle ScholarPubMed
Maurin, M. Francisella tularensis as a potential agent of bioterrorism? Expert Rev Anti Infect Ther. 2014;13(2):141144.CrossRefGoogle ScholarPubMed
Dennis, DT, Inglesby, TV, Henderson, DA, et al. Tularemia as a biological weapon. JAMA. 2001;285(21):27632773.CrossRefGoogle ScholarPubMed
Barry, EM, Cole, L, Santiago, AE. Vaccines against tularemia. Human Vaccines. 2009;5(12):832838.CrossRefGoogle ScholarPubMed
Soucheray, S, Schnirring, L. VHF. http://www.cidrap.umn.edu/infectious-disease-topics/vhf. Accessed June 2021.Google Scholar
Bradfute, SB, Dye, JJ, Bavari, S. Filovirius vaccines. Human Vaccines. 2011;7(6):701711.CrossRefGoogle ScholarPubMed
Schnirring, L. DRC Ebola total grows by 15; new antiviral clears hurdle. https://www.cidrap.umn.edu/news-perspective/2019/03/drc-ebola-total-grows-15-new-antiviral-clears-hurdle. Accessed September 2020.Google Scholar
Dudley, G, McFee, RB. Preparedness for biological terrorism in the United States: Project BioShield and Beyond. J Am Osteopath Assoc. 2005;105(9):417424.Google ScholarPubMed
Green, MS, Leduc, J, Cohen, D, Franz, DR. Confronting the threat of bioterrorism: realities, challenges, and defensive strategies. Lancet Infect Dis. 2019;19(1):e2e13.CrossRefGoogle ScholarPubMed
Zolnikov, TR. New targets for behavior change in Ebola outbreaks: ideas for future interventions. Intervention. 2018;16(2):79.CrossRefGoogle Scholar
Centers for Disease Control and Prevention (CDC). CDC calls on Americans to wear masks to prevent COVID-19 spread. https://www.cdc.gov/media/releases/2020/p0714-americans-to-wear-masks.html. Accessed June 2021.Google Scholar
Savoia, E, Lin, L, Viswanath, K. Communications in public health emergency preparedness: a systematic review of the literature. Biosecur Bioterror. 2013;11(3):170184.CrossRefGoogle ScholarPubMed